Anders Knudsen - Novozymes A/S Director, Employee Representative
NVZMF Stock | USD 54.45 1.74 3.30% |
Director
Mr. Anders Hentze Knudsen was Employee Representative on the Board of Directors at Novozymes AS since February 28, 2013. He is Senior Operator. since 2013.
Age | 59 |
Tenure | 11 years |
Phone | 45 44 46 00 00 |
Web | https://www.novozymes.com |
Novozymes A/S Management Efficiency
The company has return on total asset (ROA) of 0.1062 % which means that it generated a profit of $0.1062 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2789 %, meaning that it generated $0.2789 on every $100 dollars invested by stockholders. Novozymes A/S's management efficiency ratios could be used to measure how well Novozymes A/S manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Gerard Martiniere | Air Liquide SA | 71 | |
Jeff Fettig | Sherwin Williams Co | 64 | |
Michael Larson | Ecolab Inc | 61 | |
Matthew Thornton | Sherwin Williams Co | 62 | |
Susan Carter | Air Products and | 61 | |
Thierry Peugeot | Air Liquide SA | 58 | |
William Untiong | Dupont De Nemours | 63 | |
Margaret McGlynn | Air Products and | 59 | |
Thierry Desmarest | Air Liquide SA | 70 | |
Charles Cogut | Air Products and | 73 | |
Fred Lowery | Dupont De Nemours | N/A | |
William Davis | Air Products and | 70 | |
Joseph Tanbuntiong | Dupont De Nemours | 54 | |
Melanie Healey | PPG Industries | 59 | |
Alexander Cutler | Dupont De Nemours | 69 | |
Thomas Usher | PPG Industries | 72 | |
Vicente Perez | Dupont De Nemours | 55 | |
Annette Winkler | Air Liquide SA | 57 | |
Michael Lamach | PPG Industries | 57 | |
Jonathan Edwards | PPG Industries | N/A | |
Genevieve Berger | Air Liquide SA | 61 |
Management Performance
Return On Equity | 0.28 | |||
Return On Asset | 0.11 |
Novozymes AS B Leadership Team
Elected by the shareholders, the Novozymes A/S's board of directors comprises two types of representatives: Novozymes A/S inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novozymes. The board's role is to monitor Novozymes A/S's management team and ensure that shareholders' interests are well served. Novozymes A/S's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novozymes A/S's outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Videbaek, COO and Executive VP of Bus. Devel. | ||
Tobias Bjorklund, Head of Investor Relations | ||
Ester Baiget, Pres CEO | ||
Kasim Kutay, Director | ||
Anders Lund, Executive Vice President Household Care & Technical Industries | ||
Agnete RaaschouNielsen, Director | ||
Thomas Nagy, Executive VP of Supply Operations | ||
Pedro Fernandes, Head America | ||
Joergen Rasmussen, Independent Director | ||
Andrew Fordyce, Executive VP of Food and Beverages | ||
Lena Halskov, Director, Employee Representative | ||
Tue Micheelsen, VP Marketing | ||
Sebastian Sderberg, VP Acquisitions | ||
Martin Riise, Head of Investor Relations | ||
Peder Nielsen, CEO and Pres | ||
Prisca HavranekKosicek, CFO | ||
HeinzJuergen Bertram, Independent Director | ||
Benny Loft, CFO and Executive VP | ||
Anders Knudsen, Director, Employee Representative | ||
Lena Olving, Independent Director | ||
Mathias Uhlen, Independent Director | ||
Graziela Malucelli, Supply Operations | ||
Patricia Malarkey, Director | ||
Henrik Gurtler, Chairman of the Board | ||
Per Falholt, Consultant | ||
Kim Stratton, Director | ||
Tina Fanoe, Executive Vice President Agriculture & Bioenergy | ||
Lena Holskov, Director, Employee Representative | ||
Morten Rasmussen, Sustainability People | ||
Thomas Bomhoff, Head of Investor Relations | ||
Lars Green, Director | ||
MSc MSc, Ex CFO | ||
Lars Koeppler, Independent Director, Employee Representative |
Novozymes Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Novozymes A/S a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.28 | |||
Return On Asset | 0.11 | |||
Profit Margin | 0.21 % | |||
Operating Margin | 0.26 % | |||
Current Valuation | 14.47 B | |||
Shares Outstanding | 222.86 M | |||
Shares Owned By Insiders | 8.04 % | |||
Shares Owned By Institutions | 42.30 % | |||
Price To Earning | 33.38 X | |||
Price To Book | 6.19 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novozymes AS B. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Novozymes Pink Sheet analysis
When running Novozymes A/S's price analysis, check to measure Novozymes A/S's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novozymes A/S is operating at the current time. Most of Novozymes A/S's value examination focuses on studying past and present price action to predict the probability of Novozymes A/S's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novozymes A/S's price. Additionally, you may evaluate how the addition of Novozymes A/S to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |